"With our China NPP Group Procurement Program, orphan and clinically urgent drugs can reach Chinese patients in months—not years—through fully compliant fast-track pathways," said Mike Zhou, CEO of ACA Pharma. Post this "China's pediatric and rare-disease hospitals are telling us clearly which therapies they need most, and our job is to turn those requests into practical, compliant access pathways," said Mike Zhou, CEO, ACA Pharma. "By combining group NPP access with 30–90 day Macau registration, we can he ...